These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 17401433)

  • 21. Characterization of the p53-rescue drug CP-31398 in vitro and in living cells.
    Rippin TM; Bykov VJ; Freund SM; Selivanova G; Wiman KG; Fersht AR
    Oncogene; 2002 Mar; 21(14):2119-29. PubMed ID: 11948395
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutant p53: an oncogenic transcription factor.
    Strano S; Dell'Orso S; Di Agostino S; Fontemaggi G; Sacchi A; Blandino G
    Oncogene; 2007 Apr; 26(15):2212-9. PubMed ID: 17401430
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro analysis of the dominant negative effect of p53 mutants.
    Chène P
    J Mol Biol; 1998 Aug; 281(2):205-9. PubMed ID: 9698540
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of mutations on peptide models of the DNA binding helix of p53: evidence for a correlation between structure and tumorigenesis.
    Trulson JA; Millhauser GL
    Biopolymers; 1999 Mar; 49(3):215-24. PubMed ID: 9990839
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transcription regulation by mutant p53.
    Weisz L; Oren M; Rotter V
    Oncogene; 2007 Apr; 26(15):2202-11. PubMed ID: 17401429
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Restoring wild-type conformation and DNA-binding activity of mutant p53 is insufficient for restoration of transcriptional activity.
    Brazda V; Muller P; Brozkova K; Vojtesek B
    Biochem Biophys Res Commun; 2006 Dec; 351(2):499-506. PubMed ID: 17070499
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [TP53 mutations and molecular epidemiology].
    Otsuka K; Ishioka C
    Gan To Kagaku Ryoho; 2007 May; 34(5):683-9. PubMed ID: 17496437
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Dominant negative activity of mutated p53 proteins].
    Dridi W; Krabchi K; Gadji M; Lavoie J; Bronsard M; Fetni R; Drouin R
    Med Sci (Paris); 2006 Mar; 22(3):301-7. PubMed ID: 16527213
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutant p53 reactivation by small molecules makes its way to the clinic.
    Bykov VJ; Wiman KG
    FEBS Lett; 2014 Aug; 588(16):2622-7. PubMed ID: 24768524
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors. Part 4: p53 signaling pathway.
    Newton HB
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):177-91. PubMed ID: 15757449
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New insights into p53 function from structural studies.
    Arrowsmith CH; Morin P
    Oncogene; 1996 Apr; 12(7):1379-85. PubMed ID: 8622853
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structural and functional basis for therapeutic modulation of p53 signaling.
    Bassett EA; Wang W; Rastinejad F; El-Deiry WS
    Clin Cancer Res; 2008 Oct; 14(20):6376-86. PubMed ID: 18927276
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative assessment of the functional p53 status in glioma cells.
    Kim EL; Yoshizato K; Kluwe L; Meissner H; Warnecke G; Zapf S; Westphal M; Deppert W; Giese A
    Anticancer Res; 2005; 25(1A):213-24. PubMed ID: 15816541
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Change in oligomerization specificity of the p53 tetramerization domain by hydrophobic amino acid substitutions.
    Stavridi ES; Chehab NH; Caruso LC; Halazonetis TD
    Protein Sci; 1999 Sep; 8(9):1773-9. PubMed ID: 10493578
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The interaction of p53 with replication protein A mediates suppression of homologous recombination.
    Romanova LY; Willers H; Blagosklonny MV; Powell SN
    Oncogene; 2004 Dec; 23(56):9025-33. PubMed ID: 15489903
    [TBL] [Abstract][Full Text] [Related]  

  • 36. p53 must be competent for transcriptional regulation to suppress tumor formation.
    Nistér M; Tang M; Zhang XQ; Yin C; Beeche M; Hu X; Enblad G; van Dyke T; Wahl GM
    Oncogene; 2005 May; 24(22):3563-73. PubMed ID: 15750633
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structural studies on mechanisms to activate mutant p53.
    Viadiu H; Fronza G; Inga A
    Subcell Biochem; 2014; 85():119-32. PubMed ID: 25201192
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Complementation of two mutant p53: implications for loss of heterozygosity in cancer.
    Demidenko ZN; Fojo T; Blagosklonny MV
    FEBS Lett; 2005 Apr; 579(10):2231-5. PubMed ID: 15811347
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptides.
    Tal P; Eizenberger S; Cohen E; Goldfinger N; Pietrokovski S; Oren M; Rotter V
    Oncotarget; 2016 Mar; 7(11):11817-37. PubMed ID: 26943582
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database.
    Petitjean A; Mathe E; Kato S; Ishioka C; Tavtigian SV; Hainaut P; Olivier M
    Hum Mutat; 2007 Jun; 28(6):622-9. PubMed ID: 17311302
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.